Dashboard
The company has declared Negative results for the last 3 consecutive quarters
- PAT(Q) At Rs -2.57 cr has Fallen at -338.1% (vs previous 4Q average)
- ROCE(HY) Lowest at -2.30%
- NET SALES(Q) Lowest at Rs 7.15 cr
Stock is technically in a Bearish range
Risky - Negative Operating Profits
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 231 Cr (Micro Cap)
NA (Loss Making)
40
0.00%
-0.31
-4.43%
2.56
Total Returns (Price + Dividend) 
Zenotech Lab. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Zenotech Laboratories Ltd is Rated Strong Sell
Zenotech Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read More
Zenotech Laboratories Ltd Valuation Shifts Signal Elevated Risk Amid Sector Challenges
Zenotech Laboratories Ltd has experienced a marked deterioration in its valuation parameters, shifting from a previously expensive profile to a risky classification. This change, coupled with negative returns relative to the Sensex and underwhelming profitability metrics, raises significant concerns for investors within the Pharmaceuticals & Biotechnology sector.
Read More
Zenotech Laboratories Ltd is Rated Strong Sell
Zenotech Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 24 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 28 October 2026, providing investors with the latest perspective on the company’s position.
Read More Announcements 
Board Meeting Outcome for Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2026.
28-Oct-2026 | Source : BSESubmission of Unaudited Financial Results of the Company for the quarter and half year ended September 30 2026.
Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026
28-Oct-2026 | Source : BSEApproval for Unaudited Financial Results of the Company for the quarter and half year ended September 30 2026.
Board Meeting Intimation for Considering And Approving Unaudited Standalone Financial Results Of The Company For The Quarter And Half Year Ended September 30 2026.
17-Oct-2026 | Source : BSEZenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 inter alia to consider and approve Unaudited Standalone Financial Results for the quarter and half year ended September 30 2026.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Zenotech Laboratories Ltd has announced 17:22 rights issue, ex-date: 01 Jun 17
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Sun Pharmaceutical Industries Limited (68.84%)
Padmasree Chigurupati (5.52%)
24.22%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is -36.15% vs 8.23% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -458.70% vs 85.40% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 6.97% vs -5.92% in Sep 2024
Growth in half year ended Sep 2025 is -94.32% vs -38.32% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 10.19% vs -2.83% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -51.96% vs -43.32% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 1.49% vs 6.04% in Mar 2025
YoY Growth in year ended Mar 2026 is -119.07% vs -32.41% in Mar 2025